BACKGROUND The pathophysiology of renal disease progression in autosomal-dominant polycystic kidney disease (ADPKD) involves not only cystogenesis but also endothelial dysfunction, leading to the activation of inflammatory and fibrotic pathways. This study evaluated the levels of biomarkers related to osmoregulation, immune system activation, and tubular injury in ADPKD patients with impaired or preserved renal function. METHODS This study included 26 ADPKD patients with modestly impaired renal function (estimated glomerular filtration rate [eGFR] 45-70 mL/min/1.73 m2; Group A), 26 age- and sex-matched ADPKD patients with relatively preserved renal function (eGFR >70 mL/min/1.73 m2; Group B), and 26 age- and sex-matched controls (G...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine con...
The observational study by Boertin et al makes a valuable contribution to the research field of prev...
Background and objectives Experimental studies suggest a detrimental role for vasopressin in the pat...
Background: Experimental studies indicate that arginine vasopressin (AVP) may have deleterious effec...
Background: Experimental studies indicate that arginine vasopressin (AVP) may have deleterious effec...
Background and objectives Plasma copeptin, a marker of arginine vasopressin, is elevated in patients...
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the i...
Background/Aims: The pathophysiology of renal disease progression in autosomal dominant polycystic d...
Background: In this study, we examined the relative usefulness of serum copeptin levels as a surroga...
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder l...
Background: Our aim was to test if plasma copeptin, a stable surrogate marker of arginine vasopressi...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine con...
The observational study by Boertin et al makes a valuable contribution to the research field of prev...
Background and objectives Experimental studies suggest a detrimental role for vasopressin in the pat...
Background: Experimental studies indicate that arginine vasopressin (AVP) may have deleterious effec...
Background: Experimental studies indicate that arginine vasopressin (AVP) may have deleterious effec...
Background and objectives Plasma copeptin, a marker of arginine vasopressin, is elevated in patients...
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the i...
Background/Aims: The pathophysiology of renal disease progression in autosomal dominant polycystic d...
Background: In this study, we examined the relative usefulness of serum copeptin levels as a surroga...
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder l...
Background: Our aim was to test if plasma copeptin, a stable surrogate marker of arginine vasopressi...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
Background: Disease monitoring of autosomal dominant polycystic kidney disease (ADPKD) will become m...
BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine con...